Our aims in this competitive renewal application are shaped by our observations during the previous funding period that confirmed the critical role of cyclooxygenase (COX)-2 in cancer invasion and metastasis. We found that COX-2 was induced in hostile environments and played a critical role in mediating invasion and metastasis. COX-2 expression also increased following treatment with a conventional chemotherapy agent, 5-fluorouracil. Molecular characterization and functional imaging have identified new functional roles for COX-2 that have created new possibilities for more effective COX-2 targeting, and for imaging COX-2 expression and activity. Our data demonstrated the importance of targeting this pathway in cancer, and finding strategies to image COX-2 expression and activity. These data highlighted the importance of expanding our understanding of the role of COX-2 in altering the tumor phenotype to identify additional pathways, networks, and targets that mediate these alterations, and the importance of noninvasively identifying tumors that have increased COX-2 expression, to select for COX-2 targeting. These observations have led us to focus on three new aims that will advance our understanding of the role of inflammation in cancer progression, treatment and metastasis. These studies will be performed using triple negative human breast cancer xenograft models with different COX-2 expression levels. Our purpose in Aim 1 will be to identify the molecular causes of the effect of COX-2 on choline metabolism. These studies can uncover new biomarkers and new targets to use in combination with COX-2 targeting, to achieve improved effectiveness.
In Aim 2 we will investigate the role of COX-2 in altering the extracellular matrix structure and function using imaging.
In Aim 3 we will develop optical and MRS based probes to report on COX-2 expression and activity that may, in the future, lead to clinically translatable 19F MRS probes to detect COX-2 activity. The studies in this application will advance our insight and identify new strategies to exploit this critically important target in cancer treatment.

Public Health Relevance

COX-2 is a critically important target in cancer that significantly influences a range of characteristics such as angiogenesis, invasion and metastasis. In this application we intend to uncover new targets that interact with COX-2, and identify the effect of COX-2 expression on extracellular matrix structure and function. We also intend to develop probes to noninvasively image COX-2 expression and activity that will allow us to further understand the role of this enzyme in cancer and allow us to effectively target it.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA082337-11
Application #
8108708
Study Section
Medical Imaging Study Section (MEDI)
Program Officer
Mohla, Suresh
Project Start
1999-07-01
Project End
2016-03-31
Budget Start
2011-04-01
Budget End
2012-03-31
Support Year
11
Fiscal Year
2011
Total Cost
$295,200
Indirect Cost
Name
Johns Hopkins University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Shah, Tariq; Krishnamachary, Balaji; Wildes, Flonne et al. (2018) Molecular causes of elevated phosphoethanolamine in breast and pancreatic cancer cells. NMR Biomed 31:e3936
Goggins, Eibhlin; Kakkad, Samata; Mironchik, Yelena et al. (2018) Hypoxia Inducible Factors Modify Collagen I Fibers in MDA-MB-231 Triple Negative Breast Cancer Xenografts. Neoplasia 20:131-139
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Bhujwalla, Zaver M; Kakkad, Samata; Chen, Zhihang et al. (2018) Theranostics and metabolotheranostics for precision medicine in oncology. J Magn Reson 291:141-151
Chen, Zhihang; Krishnamachary, Balaji; Penet, Marie-France et al. (2018) Acid-degradable Dextran as an Image Guided siRNA Carrier for COX-2 Downregulation. Theranostics 8:1-12
Penet, Marie-France; Kakkad, Samata; Pathak, Arvind P et al. (2017) Structure and Function of a Prostate Cancer Dissemination-Permissive Extracellular Matrix. Clin Cancer Res 23:2245-2254
Krishnamachary, Balaji; Stasinopoulos, Ioannis; Kakkad, Samata et al. (2017) Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts. Oncotarget 8:17981-17994
Penet, Marie-France; Chen, Zhihang; Mori, Noriko et al. (2016) Magnetic Resonance Spectroscopy of siRNA-Based Cancer Therapy. Methods Mol Biol 1372:37-47
Chen, Zhihang; Penet, Marie-France; Krishnamachary, Balaji et al. (2016) PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer. Biomaterials 80:57-67
Funaro, Michael G; Nemani, Krishnamurthy V; Chen, Zhihang et al. (2016) Effect of alginate microencapsulation on the catalytic efficiency and in vitro enzyme-prodrug therapeutic efficacy of cytosine deaminase and of recombinant E. coli expressing cytosine deaminase. J Microencapsul 33:64-70

Showing the most recent 10 out of 69 publications